Risk models predicting survival after reduced-intensity transplantation for myelofibrosis

British Journal of Haematology

Volumn 157, Issue 1, 2012, Pages 75-85

  Alchalby, Haefaa ^a   Yunus, Dinah Rohina ^a   Zabelina, Tatjana ^a   Kobbe, Guido ^b   Holler, Ernst ^c   Bornhäuser, Martin ^d   Schwerdtfeger, Rainer ^e   Bethge, Wolfgang ^f   Kvasnicka, Hans Michael ^g   Büsche, Guntram ^h   Ayuk, Francis ^a   Bacher, Ulrike ^a   Zander, Axel R ^a   Kröger, Nicolaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e DKD Clinic   (Germany)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^g GOETHE UNIVERSITY   (Germany)

^h HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Allogeneic stem cell transplantation; Myelofibrosis; Risk model

Indexed keywords

HEMOGLOBIN; JANUS KINASE 2;

ADULT; AGE; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLAST CELL; BLOOD GROUP TYPING; CERVANTES SCORE; COHORT ANALYSIS; CYTOGENETICS; CYTOMEGALOVIRUS; DONOR; DYNAMIC INTERNATIONAL PROGNOSTIC SCORING SYSTEM; FEMALE; GENDER; GRAFT VERSUS HOST REACTION; HEMOGLOBIN BLOOD LEVEL; HIGH RISK POPULATION; HLA MATCHING; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LEUKOCYTE COUNT; LIFE EXPECTANCY; LILLE SCORE; MAJOR CLINICAL STUDY; MALE; MODIFIED EUROPEAN BLOOD AND MARROW TRANSPLANTATION GROUP SCORE; MORTALITY; MULTIVARIATE COX MODEL; MYELOFIBROSIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SEROLOGY; SPLENOMEGALY; STATISTICAL MODEL; SURVIVAL TIME; SYMPTOM; TREATMENT OUTCOME;

ADULT; AGED; AMINO ACID SUBSTITUTION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MUTATION, MISSENSE; PRIMARY MYELOFIBROSIS; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84858296063     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.09009.x     Document Type: Article

References (23)

1. Alchalby, H., Badbaran, A., Zabelina, T., Kobbe, G., Hahn, J., Wolff, D., Bornhauser, M., Thiede, C., Baurmann, H., Bethge, W., Hildebrandt, Y., Bacher, U., Fehse, B., Zander, A.R. & Kroger, N. (2010) Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood, 116, 3572-3581.
2. Bacigalupo, A., Soraru, M., Dominietto, A., Pozzi, S., Geroldi, S., Van Lint, M.T., Ibatici, A., Raiola, A.M., Frassoni, F., De Stefano, F., Verdiani, S., Casarino, L. & Barosi, G. (2010) Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplantation, 45, 458-463.
3. Ballen, K.K., Shrestha, S., Sobocinski, K.A., Zhang, M.J., Bashey, A., Bolwell, B.J., Cervantes, F., Devine, S.M., Gale, R.P., Gupta, V., Hahn, T.E., Hogan, W.J., Kroger, N., Litzow, M.R., Marks, D.I., Maziarz, R.T., McCarthy, P.L., Schiller, G., Schouten, H.C., Roy, V., Wiernik, P.H., Horowitz, M.M., Giralt, S.A. & Arora, M. (2010) Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant, 16, 358-367.
4. Cervantes, F., Barosi, G., Demory, J.L., Reilly, J., Guarnone, R., Dupriez, B., Pereira, A. & Montserrat, E. (1998) Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. British Journal of Haematology, 102, 684-690.
5. Cervantes, F., Passamonti, F. & Barosi, G. (2008) Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia, 22, 905-914.
6. Cervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J.T., Morra, E., Vannucchi, A.M., Mesa, R.A., Demory, J.L., Barosi, G., Rumi, E. & Tefferi, A. (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood, 113, 2895-2901.
7. Deeg, H.J., Gooley, T.A., Flowers, M.E., Sale, G.E., Slattery, J.T., Anasetti, C., Chauncey, T.R., Doney, K., Georges, G.E., Kiem, H.P., Martin, P.J., Petersdorf, E.W., Radich, J., Sanders, J.E., Sandmaier, B.M., Warren, E.H., Witherspoon, R.P., Storb, R. & Appelbaum, F.R. (2003) Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood, 102, 3912-3918.
8. Dupriez, B., Morel, P., Demory, J.L., Lai, J.L., Simon, M., Plantier, I. & Bauters, F. (1996) Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood, 88, 1013-1018.
9. Gangat, N., Caramazza, D., Vaidya, R., George, G., Begna, K., Schwager, S., Van Dyke, D., Hanson, C., Wu, W., Pardanani, A., Cervantes, F., Passamonti, F. & Tefferi, A. (2011) DIPSS Plus: a refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status. Journal of Clinical Oncology, 29, 392-397.
10. Gratwohl, A., Hermans, J., Goldman, J.M., Arcese, W., Carreras, E., Devergie, A., Frassoni, F., Gahrton, G., Kolb, H.J., Niederwieser, D., Ruutu, T., Vernant, J.P., de Witte, T. & Apperley, J. (1998) Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic leukemia working party of the European group for blood and marrow transplantation. Lancet, 352, 1087-1092.
11. Gratwohl, A., Stern, M., Brand, R., Apperley, J., Baldomero, H., de Witte, T., Dini, G., Rocha, V., Passweg, J., Sureda, A., Tichelli, A. & Niederwieser, D. (2009) Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer, 115, 4715-47260.
12. Guardiola, P., Anderson, J.E., Bandini, G., Cervantes, F., Runde, V., Arcese, W., Bacigalupo, A., Przepiorka, D., O'Donnell, M.R., Polchi, P., Buzyn, A., Sutton, L., Cazals-Hatem, D., Sale, G., de Witte, T., Deeg, H.J. & Gluckman, E. (1999) Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood, 93, 2831-2838.
13. Hussein, K., Pardanani, A.D., Van Dyke, D.L., Hanson, C.A. & Tefferi, A. (2010) International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Blood, 115, 496-499.
14. Kerbauy, D.M., Gooley, T.A., Sale, G.E., Flowers, M.E., Doney, K.C., Georges, G.E., Greene, J.E., Linenberger, M., Petersdorf, E., Sandmaier, B.M., Scott, B.L., Sorror, M., Stirewalt, D.L., Stewart, F.M., Witherspoon, R.P., Storb, R., Appelbaum, F.R. & Deeg, H.J. (2007) Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant, 13, 355-365.
15. Kroger, N., Zabelina, T., Schieder, H., Panse, J., Ayuk, F., Stute, N., Fehse, N., Waschke, O., Fehse, B., Kvasnicka, H.M., Thiele, J. & Zander, A. (2005) Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. British Journal Haematology, 128, 690-697.
16. Kroger, N., Holler, E., Kobbe, G., Bornhauser, M., Schwerdtfeger, R., Baurmann, H., Nagler, A., Bethge, W., Stelljes, M., Uharek, L., Wandt, H., Burchert, A., Corradini, P., Schubert, J., Kaufmann, M., Dreger, P., Wulf, G.G., Einsele, H., Zabelina, T., Kvasnicka, H.M., Thiele, J., Brand, R., Zander, A.R., Niederwieser, D. & de Witte, T.M. (2009) Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood, 114, 5264-5270.
17. Morel, P. & Duhamel, A. (2010) Comparison of prognostic scoring systems in primary myelofibrosis. Blood, 115, 745.
18. Passamonti, F., Cervantes, F., Vannucchi, A.M., Morra, E., Rumi, E., Cazzola, M. & Tefferi, A. (2010) Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood, 116, 2857-2858.
19. Robin, M., Tabrizi, R., Mohty, M., Furst, S., Michallet, M., Bay, J.O., Cahn, J.Y., De Coninck, E., Dhedin, N., Bernard, M., Rio, B., Buzyn, A., Huynh, A., Bilger, K., Bordigoni, P., Contentin, N., Porcher, R., Socie, G. & Milpied, N. (2011) Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). British Journal Haematology, 152, 331-339.
20. Tam, C.S., Kantarjian, H., Cortes, J., Lynn, A., Pierce, S., Zhou, L., Keating, M.J., Thomas, D.A. & Verstovsek, S. (2009) Dynamic model for predicting death within 12months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Journal of Clinical Oncology, 27, 5587-5593.
21. Tefferi, A., Huang, J., Schwager, S., Li, C.Y., Wu, W., Pardanani, A. & Mesa, R.A. (2007) Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer, 109, 2083-2088.
22. Tefferi, A., Vaidya, R., Caramazza, D., Finke, C., Lasho, T. & Pardanani, A. (2011) Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling Study. Journal of Clinical Oncology, 29, 1356-1363.
23. Thiele, J., Kvasnicka, H.M., Facchetti, F., Franco, V., van der Walt, J. & Orazi, A. (2005) European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica, 90, 1128-1132.